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Background: Universities, public institutions, and the transfer of knowledge to the private sector play a major
role in the development of medical technologies. The decisions of universities and public institutions regarding the
transfer of knowledge impact the accessibility of the final product, making it easier or more difficult for consumers
to access these products. In the case of medical research, these products are pharmaceuticals, diagnostics, or
medical procedures. The ethical dimension of access to these potentially lifesaving products is apparent and
distinguishes the transfer of medical knowledge from the transfer of knowledge in other areas. While the general
field of technology transfer from academic and public to private actors is attracting an increasing amount of
scholarly attention, the specifications of knowledge transfer in the medical field are not as well explored. This
review seeks to provide a systematic overview and analysis of the qualitative literature on the characteristics and
determinants of knowledge transfer in medical research and development.
Methods: The review systematically searches the literature for qualitative studies that focus on knowledge transfer
characteristics and determinants at medical academic and public research institutions. It aims at identifying and
analyzing the literature on the content and context of knowledge transfer policies, decision-making processes, and
actors at academic and public institutions. The search strategy includes the databases PubMed, Web of Science,
ProQuest, and DiVa. These databases will be searched based on pre-specified search terms. The studies selected
for inclusion in the review will be critically assessed for their quality utilizing the Qualitative Research Checklist
developed by the Clinical Appraisal Skills Programme. Data extraction and synthesis will be based on the
meta-ethnographic approach.
Discussion: This review seeks to further the understanding of the kinds of transfer pathways that exist in medical
knowledge transfer as well as what factors lead to the adoption of one pathway over another. The aim is to
provide evidence for political and academic actors designing policies for the translation of medical knowledge
and public-private cooperation.
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Universities and public institutions play an important role
in the development of new technologies in medicine.1 A
2010 study examining all pharmaceuticals developed
between 1998 to 2007 found that of those pharmaceuticals
classified as scientifically novel, more than 30 % originated
from universities and were later developed by pharma-
ceutical or biotech companies [1]. This illustrates the role
the public sector and the interaction between private and
public actors play in the development of new medicines
and medical technologies. The nature of this interaction
has a great impact not only on the kinds of medicines that
are developed but also on how well they are accessible.
For example, the first candidates for the HPV vaccines
preventing cervical cancer, Gardasil, and Cervarix, were
developed by public institutions and universities [2]. These
were later licensed to Glaxo Smith Kline and Merck
Sharpe and Dohme. As the licenses were exclusive, only
these two companies had the right to develop and sell the
resulting vaccines when they came to market in 2006 and
2009 [3]. The resulting lack of competition has led to high
prices, making it difficult for poorer populations to afford
vaccination. However, HPV disproportionately affects the
world’s poor, with over 80 % of the cases occurring in
developing countries [4].
As the case of the HPV vaccine illustrates, furthering the
understanding of how universities and public institutions
transfer their technologies is of great interest to public
health professionals. However, while university technology
transfer in general has attracted an increasing amount of
scholarly attention, the transfer of knowledge in the devel-
opment of new medical technologies specifically has rarely
been addressed.
However, “anyone studying technology transfer under-
stands just how complicated it can be” [5]. Defining the
terms “technology” and “transfer” is the first challenge.
According to the “system’s view of technology” [6], tech-
nology can be described as a system of processes and
products and the knowledge of their use and production.
The process of innovation is an evolution of this system
and its configuration. Basic principles serve as a guide for
further development, and breakthroughs result from the
culmination of prior, smaller changes to it. These then in
turn form the basis for new developments in a continuous
evolutionary process of innovation. This evolutionary
process of innovation makes it difficult to demarcate
individual technologies [6].
In addition to “technology”, the term “knowledge” has
also been used, albeit without a clear distinction between
the two terms. Sahal argues that whenever a technology is
transferred, the knowledge of its use and its production
process has to be transferred with it. Thus, “the knowledge
base is inherent, not ancillary” [5]. For the purpose of this
review, the broader term “knowledge” is used and definedto include “technology”. According to the “system’s view
of technology”, any new knowledge, or minor modification
of existing knowledge, is part of the innovation process,
making it unnecessary to demarcate specific technologies
[6]. Therefore, this review involves studies that address
the exchange of any scientific knowledge generated by a
researcher at a public institution or university.
The scope of the word “transfer” has been the subject of
discussions as well. One definition commonly used in
empirical studies is “transfer of physical devices, techno-
logical processes, or ‘know how’ from your organization to
another” [7]. In medical research, two types of knowledge
transfer can be discerned. The first consists of the
utilization of basic medical research for the “development
of new methods for diagnosis, therapy, and prevention
and their first testing in humans”, while the second
describes the “translation of results from clinical studies
into everyday clinical practice and health decision-
making”. [8–10] In this study, we address the first type of
knowledge transfer. However, as the two processes are
closely related, our conceptual findings might be relevant
for the study of knowledge translation into practice as
well.
A suggested model of “transfer” in the context of
university research was developed by Bradley, Hayter,
and Link [11]. Their “new model of university technol-
ogy transfer” distinguishes two main types of technology
transfer—formal transfer (through the technology trans-
fer office) and informal transfer (informal exchange with
colleagues, conferences, etc.). They argue that the scien-
tist, as the originator of the knowledge, is central to the
transfer process. He/she decides whether or not to de-
clare an invention to the institution’s technology transfer
office (TTO). If the researcher declares the invention,
the TTO can decide whether to patent the discovery or
not. If it chooses to patent, it markets the innovation to
a third party or founds a new company to commercialize
the invention, a so-called spin-off; if it does not patent
the invention, the knowledge enters the public domain
or is claimed by the scientist. However, new knowledge
that is not declared by the scientist as an invention can
be transferred informally, at conferences, through joint
publications or informal meetings. According to Bradley,
Hayter, and Link, these different transfer pathways can
happen in various ways and often simultaneously [11].
However, this concept is limited in scope, as it only
includes transfer processes that arise from a, usually
patentable, discovery and ends with the adoption of a
product. It does not take into account collaborative
research, especially if it precedes discovery, and transfer
processes that do not have the goal of commercializing a
product. This gap is filled by the concept of academic
engagement, which includes all “knowledge related col-
laboration by academic researchers with non-academic
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alternative view of technology transfer in so far as the focus
is less on “transfer” and more on “collaboration” between
institutions, often based on individual interaction. Its focus
is broader, it does not stipulate an immediate financial
objective but acknowledges that some collaborations aim at
generating a more vague kind of utility. Combined, aca-
demic engagement and the alternative view of university
technology transfer provide a comprehensive basis for
analyzing knowledge exchange between public and private
research entities. This study seeks to review the qualitative
literature on the formal or informal transfer of medical
knowledge from public and academic research institutions
to private entities. We aim to improve the understanding of
public-private knowledge transfer by addressing four key
questions: What is the context in which knowledge transfer
occurs? What are possible transfer pathways? What is the
process by which a pathway is chosen? Who are the actors
involved in the decision-making and what power do they
have?
Methods/design
This review will include studies that address any kind of
formal or informal method to transfer knowledge created
at public institutions or universities to the private sector;
and the factors that determine which of the possible
policies is adopted. However, the scope of this literature
review is limited to qualitative studies. Qualitative research
“is most revealing when the variables of greatest concern
are unclear” [13]. The questions of what the possible know-
ledge transfer methods are and what determines which
strategy scientists and university staff apply are therefore
properly addressed through qualitative research.
Search strategy
The search strategy aims at finding both published and
unpublished studies. A three-step search strategy will be
utilized. In the first step, keywords for the search haveTable 1 Databases and search terms
Database: Term:
PubMed (medical OR medicine OR biomedical OR pharmaceutical OR
public institut*) AND (Technology OR innovation OR knowled
((Joint OR collaborative OR contract) AND research)) AND (in
Web of
Science
(medic* OR biomedical OR pharmaceutical* OR biotech) AND
institution) AND (Technology OR innovation* OR knowledge)
((Joint OR collaborative OR contract) research)) AND (industry
ProQuest AB((medical OR biomedical OR pharmaceutical) AND (univers
research) OR “public institution”) AND (Technology OR innov
NEAR/5 Industry near/5 collabor*)) AND (industry OR “private
DiVa (medical OR biomedical OR pharmaceutical) AND (university
institution”) AND (Technology OR innovation) AND (Transfer
“private sector”)
DART -
Europe
(medical OR biomedical OR pharmaceutical) AND (university
innovation) AND (Transfer OR Translation OR commercializatibeen developed based on the PICo approach. The PICo
mnemonic has been developed for systematic reviews of
qualitative literature, its components are population (P),
phenomenon of interest (I), and context (Co). In compari-
son to quantitative reviews, it does not include an
outcome, as “the expression of the phenomena of interest
is the outcome.” [14] In the case of this review, scientists at
universities and public research institutions represent the
population, knowledge transfer, the phenomenon of inter-
est, and medical research and development the context.
The databases to be searched are PubMed and Web of
Science. The search for unpublished studies will include
ProQuest and DiVA. Initial keywords included: research,
development, medical, pharmaceutical, biomedical, uni-
versity, academia, publicly funded, technology, innovation,
results, discovery, knowledge, patent, transfer, translation,
commercialization, transfer method, transfer pathway,
transfer process, license, formal, informal. For full search
terms, see Table 1. The keywords were used in a cursory
search of PubMed, Web of Science, ProQuest, and DiVA.
The first results of this limited search were evaluated for
relevance and the search terms were refined accordingly
and adapted to the respective database. In the second step,
a full search of the databases was undertaken using the
refined and prespecified search terms.
A pre-selection based on title and abstract will be identi-
fied by applying the inclusion and exclusion criteria. A
random set of 10 % of the studies will be pre-selected in
duplicate (RJ, KB) to test the criteria for inclusion and
exclusion and establish a consensus on the selection pro-
cedure. The remainder of the studies will be pre-selected
by one researcher (RJ), unclear cases will be discussed in
the review team.
The research team then scans the full text articles,
again applying the inclusion and exclusion criteria.
Studies published in German and English and between
1995 and 2014 will be considered for inclusion in this
review. This is because the major international agreementbiotech) AND (university OR academic OR universities OR facult* OR
ge) AND (Transfer OR Translation OR commercialization OR License OR
dustry OR “private sector” OR company)
(universit* OR academic OR facult* OR publicly funded OR public
AND (Transfer OR Translation Or commercialization OR License OR
OR “private sector” OR company)
ity OR academic* OR faculty* OR (public* NEAR/2 fund* NEAR/2
ation) AND (Transfer OR Translation OR commercialization OR (University
sector” OR compan*))
OR academic OR faculty OR “publicly funded research” OR “public
ORTranslation OR commercialization OR collabor*) AND (industry OR
OR academic OR faculty OR “public institution”) AND (Technology OR
on OR collabor* OR industry OR “private sector”)
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Related Aspects of Intellectual Property” (TRIPS), includ-
ing medical inventions, entered into force on 1 January
1995 and led to a restructuring of technology transfer
nationally and internationally [15].
The resulting studies will be critically appraised for
their quality using the qualitative research checklist de-
veloped by the Critical Appraisal Skills Programme
(CASP) [16], and data will be extracted. The data will
be analyzed using the meta-ethnographic approach. To
ensure relevance to policy makers, the synthesis will be
framed in accordance with the health policy triangle, a
policy analysis framework developed by Gill Walt and
Lucy Gilson (1994).Inclusion criteria
The systematic review will include primary research
studies that focus on qualitative data, cover technology
transfer policies at universities or public institutions and
address at least one of the following: a) content – possible
technology transfer policies (spin-off, types of licenses,
informal transfer, etc.), b) context – individual or institu-
tional determinants of the adoption of technology transfer
policies, c) process – procedural characteristics of decision-
making regarding technology transfer, and d) actors – infor-
mation about parties involved in the decision-making
regarding technology transfer. The studies must also cover
medical research as a single study subject or within a range
of study subjects, (medical meaning pharmaceuticals,
diagnostics, medical devices and procedures), have an
empirical or systematic approach and be peer reviewed or
dissertations.Exclusion criteria
The systematic review will exclude works that are com-
mentaries, theoretical texts, books, and meeting reports
that do not specifically address medical research and
development or focus on an industry perspective or on
effectiveness and performance of technology transfer.Critical quality appraisal
Qualitative papers selected for retrieval will be assessed
by two independent reviewers for methodological
rigour using the qualitative research checklist devel-
oped by CASP in 2012 [16]. It evaluates theoretical ap-
proach, study design, data collection, data analysis, and
ethics on the basis of ten questions. Any disagreements
in grading that arise between the reviewers will be re-
solved through discussion. The score (1–10) of each in-
cluded study will be indicated in the final report, and
the possible influence of quality issues on the overall
synthesis will be discussed.Data extraction and synthesis
Data extraction and synthesis will follow the meta-
ethnography approach first developed by Noblit and Hare.
It describes an approach whereby major themes, “meta-
phors” are identified and then compared across studies.
They describe three major strategies, of which we will
follow the “lines-of-argument synthesis” (LOA). This
approach is appropriate in cases where “many studies
suggest a lines-of-argument or inference about some lar-
ger issue or phenomenon” [17]. It allows for the synthesis
of studies that are diverse and offer an illustration of dif-
ferent aspects of a larger “whole”. This is likely to be the
case in this study because the included studies are going
to cover various aspects of knowledge transfer. Synthesis
“involves building a general interpretation grounded in
the findings of the separate studies” [18]. The findings, or
key metaphors, will be identified using open coding in
MAXQDA to allow for systematic analysis of a larger
number of studies and facilitate oversight. After extracting
the data of the first two studies, the review team will evalu-
ate and if necessary revise the extraction strategy. The
coded metaphors will be grouped according to their con-
tent so related metaphors can be analyzed and translated
into each other across studies. These translations and their
relationships will be reported in the synthesis. Data extrac-
tion and synthesis will be done in duplicate. The synthesis
of the systematic review should not just be well-grounded
in theory, but it should also be relevant and appropriate for
policy makers. Embrett and Randall have examined the
health and health equity policy literature. They have stated
that issues raised by scholars in this field rarely make it to
the policy agenda, identifying the common misuse and
nonuse of political analysis theory as one of the reasons
[19]. Therefore, this study uses the health policy triangle as
a policy analysis tool to ensure the synthesized evidence will
be relevant and useful to policy makers.
The health policy triangle is a policy analysis tool
developed by Gill Walt and Lucy Gilson. It states that
the adoption of policies depends on four aspects: con-
text, content, process and actors [20]. In the context of
this review, these aspects are:
– Context: What is the context in which knowledge
transfer occurs?
– Content: What are possible technology transfer
policies?
– Process: How is the transfer policy negotiated within
the institution and with external partners?
– Actors: Who is involved in the decision-making at
the university / public institution?
The health policy triangle will be used to frame the
synthesis in a meaningful way. Its categories are broad
enough to accommodate all findings and categories
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applied in conjunction with the meta-ethnographic
approach.
Discussion
This review seeks to further the understanding of the
kinds of transfer pathways that exist in medical knowledge
transfer as well as what factors lead to the adoption of one
pathway over another. The aim is to provide evidence for
political and academic actors designing policies for the
translation of medical knowledge and public-private
cooperation. Understanding the importance of technology
transfer and its effect on access to medicines and equality
in health, in conjunction with improved knowledge of
how this transfer comes about and why might aid individ-
ual, institutional and political actors in shaping a research
environment that is conducive to global health.
Endnotes
1For the purpose of this study, the term “public research
institution” includes all medical research entities primarily
funded from public sources.
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